Digoxin cuts heart-failure stays while ultrasound and a patch automate rescue
Low-dose digoxin cut Dutch heart-failure admissions about 25 per cent for under 10 cents daily. Ultrasound gives solid tumours a CD19 target for existing CAR-T cells, while a coin-sized patch senses fentanyl and releases naloxone.
Science··Night
Low-dose digoxin cut admissions by about 25 per cent
A randomised trial of 1,000 patients across 43 Dutch centres found that adding low-dose digoxin to standard treatment reduced hospital admissions for heart failure by about 25 per cent over roughly three years. The results appear in Nature Medicine and JAMA, and the drug costs under 10 cents a day. Patients with reduced or mildly reduced ejection fraction were randomly assigned to digoxin or a placebo alongside their usual drugs. A combined measure of cardiovascular death and worsening heart failure fell by 19 per cent, a drop that did not reach statistical significance on its own. A meta-analysis pooling this trial with two earlier ones, and a follow-up of about 600 participants after they stopped the drug, point the same way, and the group treats that follow-up as supporting evidence. Only around 15 per cent of heart-failure patients currently receive digoxin. A cheap, old molecule can cut the return trip to hospital when added to today's drug stack, while the combined death-and-worsening measure still needs a more cautious reading.[1]
SHIFTERS: a temporary CD19 stamp by ultrasound
A USC team reports in Science Advances a system called SHIFTERS that uses focused ultrasound to make solid-tumour cells display CD19, the marker CAR-T therapy already targets in blood cancers. CAR-T cells work well against blood cancers because those cells all carry CD19, while solid tumours vary too much to offer one reliable target. SHIFTERS instead delivers a genetic programme that switches on only where tumour signatures and a burst of focused ultrasound coincide, so the marker appears temporarily and lasts about a week. The team found that killing spread across a whole tumour even when only 10–25 per cent of cells displayed the marker. The work was tested in cell cultures, three-dimensional tumour models and mice carrying human brain and liver tumours. The system has not been tried in people, and the researchers say the main obstacle is getting the genetic programme into tumours, putting clinical use years away. The move is to dress a solid tumour briefly in a recognition path CAR-T cells already know, rather than hunt for one permanent antigen of its own.[2]
The iNal patch: sense fentanyl, release naloxone
Virginia Tech researchers describe iNal in Advanced Science, a microneedle patch that detects fentanyl in the skin and releases naloxone within minutes with no bystander involved. It has been tested in the laboratory and in mice, not in people. The patch carries 121 microscopic needles and can keep releasing naloxone for up to 24 hours, responding to at least three separate fentanyl exposures in testing. That detail matters because fentanyl can outlast a single dose of naloxone. The lead researcher describes the value as being protected all the time without needing a bystander. The group writes that durability over time, consistency across different skin types and accuracy in real conditions all still need work. Read together, the three tools either remeasure an old heart drug, briefly stamp a known immune target onto solid tumours, or attach emergency antidote delivery to the skin without waiting for a witness. Each tries to automate a rescue or treatment path with a small intervention next to the patient or the tumour; digoxin is already in human trials, while SHIFTERS and iNal remain at laboratory and animal stages.[3], [1], [2]
